Vasoactive intestinal peptide and nitric oxide: Divergent roles in relation to tissue injury

Annals of the New York Academy of Sciences

Volumn 805, Issue , 1996, Pages 379-387

  Said, Sami I ^a  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; GUANYLATE CYCLASE; NEUROPEPTIDE; NITRIC OXIDE; VASOACTIVE INTESTINAL POLYPEPTIDE;

CELL PROTECTION; CONFERENCE PAPER; LUNG INJURY; NEUROTRANSMITTER RELEASE; TISSUE INJURY;

EID: 0030455369     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb17498.x     Document Type: Conference Paper

References (61)

1. SAID, S. I. 1991. Vasoactive intestinal polypeptide: Biological role in health and disease. Trends Endocrinol. Metab. 2: 107-112.
2. BOECKXSTAENS, G. E., P. A. PELCKMANS, G. J. DEMAN, H. BULT, A. G. HERMAN & Y. M. VAN MAERCKE. 1992. Evidence for differential release of nitric oxide and vasoactive intestinal polypeptide by nonadrenergic noncholinergic nerves in the rat gastric fundus. Arch. Int. Pharmacodyn. Ther. 318: 107-115.
3. BULT, H., G. E. BOECKXSTAENS, P. A. PELCKMANS, F. H. JORDAENS, Y. M. VAN MAERCKE & A. G. HERMAN. 1990. Nitric oxide as an inhibitory non-adrenergic non-cholinergic neurotransmitter. Nature 345: 346-347.
4. IGNARRO, L. J., P. A. BUSH, G. M. BUGA, K. S. WOOD, J. M. FUKUTO & J. RAJFER. 1990. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem. Biophys. Res. Commun. 170:843-850.
5. LI, C. G. & M. J. RAND. 1991. Evidence that part of the NANC relaxant response of guinea-pig trachea to electrical field stimulation is mediated by nitric oxide. Eur. J. Pharmacol. 102: 91-94.
6. G-nitro arginine inhibits non-adrenergic, non-cholinergic relaxations of guinea-pig isolated tracheal smooth muscle. Br. J. Pharmacol. 100: 663-664.
7. DEY, R. D., B. MAYER & S. I. SAID. 1993. Colocalization of vasoactive intestinal peptide and nitric oxide synthase in neurons of ferret trachea. Neurosci. 54: 839-843.
8. GRIDER, J. R., K. S. MURTHY, J.-G. JIN & G. M. MAKHLOUF. 1992. Stimulation of nitric oxide from muscle cells by VIP: Prejunctional enhancement of VIP release. Am. J. Physiol. 262: G774-G778.
9. SHARAF, H. H. & S. I. SAID. 1992. VIP relaxation of airway, pulmonary artery and aortic vascular smooth muscle is unaffected by blockade of nitric oxide synthase. Am. Rev. Respir. Dis. 145: A3 82.
10. LILLY, C. M., J. S. STAMLER, B. GASTON, C. MECKEL, J. LOSCALZO & J. M. DRAZEN, 1993. Modulation of vasoactive intestinal peptide pulmonary relaxation by NO in tracheally superfused guinea pig lungs. Am. J. Physiol. 265: L410-L415.
11. SAID, S. 1.1992. Nitric oxide and vasoactive intestinal peptide as co-transmitters of smooth muscle relaxation. News Physiol. Sci. 7: 181-183.
12. SAID, S. I. 1994. VIP and nitric oxide: Physiological co-transmitters with antagonistic roles in inflammation. Biomed. Res. 15 (Suppl. 2): 79-84.
13. FODA, H. D., T. IWANAGA, L.-W. LIU & S. I. SAID. 1988. Vasoactive intestinal peptide protects against HCl-induced pulmonary edema in rats. Ann. N.Y. Acad. Sci. 527: 633-636.
14. PAKBAZ, H., L.-W. Liu, H. D. FODA, H. BERISHA & S. I. SAID. 1988. Vasoactive intestinal peptide (VIP) as a modulator of PAF-induced lung injury. Clin. Res. 36: 626A.
15. BERISHA, H., H. FODA, H. SAKAKIBARA, M. TROTZ, H. PAKBAZ & S. I. SAID. 1990. Vasoactive intestinal peptide prevents lung injury due to xanthine/xanthine oxidase. Am. J. Physiol. 259: L151-L155.
16. PAKBAZ, H., H. D. FODA, H. I. BERISHA, M. TROTZ & S. I. SAID. 1993. Paraquat-induced lung injury: Prevention by vasoactive intestinal peptide (VIP) and the related peptide helodermin. Am. J. Physiol. 265: L369-L373.
17. PAKBAZ, H., J. HIGUCHI, H. D. FODA & S. I. SAID. 1991. Phospholipase C-induced acute lung injury and its attenuation by vasoactive intestinal peptide (VIP). Am. Rev. Respir. Dis. 143: A577.
18. PAKBAZ, H., H. BERJSHA, H. SHARAF, H. D. FODA & S. I. SAID. 1994. VIP enhances, and nitric oxide synthase inhibitor reduces, survival of rat lungs perfused ex vivo. Ann. N.Y. Acad. Sci. 723: 426-428.
19. SAID, S. I., H. I. BERISHA & H. PAKBAZ. 1995. NMDA receptors outside the CNS: Activation causes acute lung injury that is mediated by nitric oxide synthesis and prevented by VIP. Neuroscience 65: 943-946.
20. SAID, S. I., H. I. BERISHA & H. PAKBAZ. 1996. Excitotoxicity in lung: N-methyl-D-aspartate-induced, nitric oxide-dependent, pulmonary edema is attenuated by vasoactive intestinal peptide and by inhibitors of poly (ADP-ribose) polymerase. Proc. Nat. Acad. Sci. U.S.A. 93: 4688-4692.
21. ALESSANDRINI, F., M. THAKKAR, H. D. FODA, H. PAKBAZ, S. I. SAID, R. LODI & D. E. SCHRAUENAGEL. 1993. Vasoactive intestinal peptide enhances lung preservation. Transplantation 56: 964-973.
22. BERISHA, H., H. PAKBAZ, S. LYUBSKY & S. I. SAID. 1995. Acute lung injury due to cobra venom factor in vivo is prevented by vasoactive intestinal peptide (VIP). Am. J. Respir. Crit. Care Med. 151: A767.
23. PAKBAZ, H., H. BERISHA, A. ABSOOD, H. D. FODA & S. I. SAID. 1995. Vasoactive intestinal peptide (VIP) as a modulator of neurogenic inflammation in airways. Am. J. Respir. Crit. Care Med. 151: A702.
24. KALFIN, R., N. MAULIK, R. M. ENGELMAN, G. A. CORDIS, K. MILENOV, L. KASAKOV & D. K. DAS. 1994. Protective role of intracoronary vasoactive intestinal peptide in ischemic and reperfused myocardium. J. Pharmacol. Exp. Ther. 288: 952-958.
25. SAID, S. I., L. P. BOSHER, J. A. SPATH & H. A. KONTOS. 1972. Positive inotropic action of newly isolated vasoactive intestinal peptide (VIP). Clin. Res. 20: 29.
26. SMITHERMAN, T. C., J. J. POPMA, S. I. SAID, G. J. KREJS & G. J. DEHMERX. 1989. Coronary hemodynamic effects of intravenous vasoactive intestinal peptide in man. Am. J. Physiol. 257: H1254-H1262.
27. ANDERSON, F. L., A. C. KRALIOS, R. HERSHBERGER & M. R. BRISTOW. 1988. Effect of vasoactive intestinal peptide on myocardial contractility and coronary blood flow in the dog: Comparison with isoproterenol and forskolin. J. Cardiovasc. Pharmacol. 12: 365-371.
28. COLSTON, J. T. & G. L. FREEMAN. 1992. Beneficial influence of vasoactive intestinal peptide on ventriculovascular coupling in closed-chest dogs. Am. J. Physiol. 263: H1300-H1305.
29. PINCUS, D. W., E. M. DI CICCO-BLOOM & I. B. BLACK. 1990. Vasoactive intestinal peptide regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts. Nature 343: 564-567.
30. PENCE, J. C. & N. A. SHORTER. 1990. In vitro differentiation of human neuroblastoma caused by vasoactive intestinal peptide. Cancer Res. 50: 5177-5183.
31. BRENXEMAN, D. E., G. L. WESTBROOK, S. P. FITZGERALD, D. L. ENNIST, K. L. ELKINS, M. R. RUFF & C. B. PERT. 1988. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature 335: 639.
32. GRESSENS, P., J. M. HILL, I. GOZES, M. FRIDKIN & D. E. BRENNEMAN. 1993. Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature 362: 155-158.
33. HILL, J. M., I. GOZES, J. L. HILL, M. FRIDKIV & D. E. BRENNEMAN. 1991. Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat. Peptides 12: 187-192.
34. OTTAWAY, C. A. 1987. Selective effects of vasoactive intestinal peptide on the mitogenic response of murine T cells. Immunology 62: 291-297.
35. ROLA-PLESZCZYNSKI, M., D. BOLDUC & S. ST.-PIERRE. 1985. The effects of vasoactive intestinal peptide on human natural killer cell function. J. Immunol. 135: 2569-2573.
36. BELLIDO, L., M. A. LÖPEZ-GONZALEZ, C. PEDRERA & M. LUCAS. 1994. Vasoactive intestinal peptide inhibits fMLP-induced respiratory burst in human lymphocytes. Life Sci. 54: 1909-1916.
37. WIIK, P. 1989. Vasoactive intestinal peptide inhibits the respiratory burst in human monocytes by a cyclic AMP-mediated mechanism. Regul. Pept. 25: 187-197.
38. UNDEM, B. J., E. C. DICK & C. K. BUCKNER. 1983. Inhibition by vasoactive intestinal peptide of antigen-induced histamine release from guinea-pig minced lung. Eur. J. Pharmacol. 88: 247-249.
39. 2 receptor blockers on degranulation. Pharmacology 43: 47-52.
40. Lrrwix, D. K., A. K. WILSON & S. I. SAID. 1992. Vasoactive intestinal polypeptide inhibits rat alveolar macrophage phagocytosis and chemotaxis. Regul. Pept. 40: 63-74.
41. DIMARZO, V., J. R. TIPPINS & H. R. MORRIS. 1988. Bradykinin- and chemotactic peptide fMLP-stimulated leukotriene biosynthesis in rat lungs and its inhibition by vasoactive intestinal peptide. Biochem. Int. 17: 235-242.
42. 2: A mechanism of anti-inflammatory activity. Regul. Pept. 48: 301-307.
43. MISRA, B. R. & H. P. MISRA. 1990. Vasoactive intestinal peptide, a singlet oxygen quencher. J. Biol. Chem. 265: 15371-15374.
44. HALLIWELL, B. & J. M. C. GUTTERIDGE. 1989. Free Radicals in Biology and Medicine. 2nd ed. Clarendon Press, Oxford.
45. 44a. MOXCADA, S., R. M. J. PALMER & E. A. HIGGS. 1991. Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol. Rev. 43: 100-142.
46. MATHEIS, G., M. P. SHERMAN, G. D. BUCKBERG, D. M. HAYBRON, H. H. YOUNG & L. J. IGNARRO. 1992. Role of L-arginine-NO pathway in myocardial reoxygenation injury. Am. J. Physiol. 262: H616-H620.
47. KUBES, P. 1993. Ischemia-reperfusion in feline small intestine: A role for nitric oxide. Am. J. Physiol. 264: G143-G149.
48. 2 toxicity. Proc. Natl. Acad. Sci. U.S.A. 89: 9715-9719.
49. WRIGHT, C., D. D. REES & S. MONCADA. 1992. Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc. Res. 26: 48-57.
50. ZEMBOWICZ, A. & J. R. VANE. 1992. Induction of nitric oxide synthase activity by toxic shock syndrome toxin 1 in a macrophage-monocyte cell line. Proc. Natl. Acad. Sci. U.S.A. 89: 2051-2055.
51. ω-amino-L-arginine. J. Natl. Cancer Inst. 84: 1008-1016.
52. KOLB, H. & V. KOLB-BACHOFEN. 1992. Nitric oxide: A pathogenetic factor in autoimmunity. Immunol. Today 13: 157-160.
53. DAWSON, V. L., T. M. DAWSON, E. D. LONDON, D. S. BREDT & S. H. SNYDER. 1991. Nitric oxide mediates glutamate neurotoxicity in primary cultures. Proc. Natl. Acad. Sci. U.S.A. 88: 6368-6371.
54. IZUMI, Y., A. M. BENZ, D. B. CLIFFORD & C. F. ZORUMSKI. 1992. Nitric oxide inhibitors attenuate N-methyl-D-aspartate excitotoxicity in rat hippocampal slices. Neurosci. Lett. 135: 227-230.
55. NOWICKI, J. P., D. DUVAL, H. POIGNET & B. SCATTON. 1991. Nitric oxide mediates neuronal death after focal cerebral ischemia in the mouse. Eur. J. Pharmacol. 204: 339-340.
56. MEYER, J., L. D. TRABER, S. NELSON, C. W. LENTZ, H. NAKAZAWA, D. N. HERNDON, H. NODA & D. L. TRABER. 1992. Reversal of hyperdynamic response to continuous endotoxin administration by inhibition of NO synthesis. J. Appl. Physiol. 73: 324-328.
57. HARBRECHT, B. G., T. R. BILLIAR, J. STADLER, A. J. DEMETRIS, J. OCHOA, R. D. CURRAN & R. L. SLMMONS. 1992. Inhibition of nitric oxide synthesis during endotoxemia promotes intrahepatic thrombosis and an oxygen radical-mediated hepatic injury. J. Leukocyte Biol. 52: 390-394.
58. ω-amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin. J. Exp. Med. 176: 1175-1182.
59. BERISHA, H. I., H. PAKBAZ, A. ABSOOD & S. I. SAID. 1994. Nitric oxide as a mediator of oxidant lung injury due to paraquat. Proc. Natl. Acad. Sci. U.S.A. 91: 7445-7449.
60. BERISHA, H., H. PAKBAZ, A. ABSOOD, H. D. FODA & S. I. SAID. 1994. Nitric oxide mediates tissue injury caused by paraquat and xanthine oxidase. Ann. N.Y. Acad. Sci. 723: 422-425.
61. MULLIGAN, M. S., J. M. HEVEL, M. A. MARLETTA & P. A. WARD. 1991. Tissue injury caused by deposition of immune complexes is L-arginine dependent. Proc. Natl. Acad. Sci. U.S.A. 88: 6338-6342.